Stevanato Group SpA (STVN) Stock AnalysisSTVNStevanato Group SpA

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

Stevanato Group (STVN) is a good buy right now due to its current price of $21.03 being significantly lower than the analyst price target of $25 from TD Cowen, indicating a potential upside of approximately 19%. Additionally, the forward P/E ratio of 7.22 suggests the stock is undervalued relative to its earnings potential. However, a risk to consider is the recent decline in net income, which dropped to €22.96 million in Q2 2026, down from €28.03 million in Q1 2026, reflecting a potential concern in profitability.